Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record.

Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study

Storey, J. R., Calder, C. S., Hart, D. E., Potter, D. L.·2001·Headache: The Journal of Head and Face Pain

Abstract

Objective.—To evaluate the efficacy of topiramate in the preventative treatment of episodic migraine. Background.—Topiramate is a broad‐spectrum antiepileptic drug effective for treatment of multiple seizure types in adults and children. Antiepileptic agents have demonstrated efficacy in migraine prevention, and open‐label experience from our clinic has suggested that topiramate might be effective for this use. We consequently conducted a single‐center, double‐blind, placebo‐controlled trial to evaluate the efficacy and safety of topiramate for the preventative treatment of migraine. Methods.—Forty patients, aged 19 to 62 years (mean, 38.2 years), were randomly assigned in a 1:1 ratio to receive topiramate (n = 19; all women) or placebo (n = 21; 20 women, 1 man). Following a prospective baseline phase of 4 weeks, the study drug dose was titrated weekly in 25‐mg increments over 8 weeks to 200 mg per day or to the maximum tolerated dose. The titration phase was followed by an 8‐week maintenance phase. Results.—During the entire double‐blind phase, topiramate‐treated patients experienced a significantly lower 28‐day migraine frequency (3.31 ± 1.7 versus 3.83 ± 2.1; P = .002) compared to placebo, irrespective of use of concomitant migraine prevention medications. The mean 28‐day migraine frequency was reduced by 36% in patients receiving topiramate as compared with 14% in patients receiving placebo ( P = .004). Twenty‐six percent of the patients on topiramate and 9.5% of the patients on placebo achieved a 50% reduction in migraine frequency ( P > .05). The mean dose of topiramate was 125 mg per day (range, 25 to 200 mg per day). Topiramate was well tolerated; 2 of 19 topiramate‐treated patients discontinued treatment due to adverse events. Adverse effects that occurred more frequently in topiramate‐treated patients included paresthesia, weight loss, altered taste, anorexia, and memory impairment. Conclusions.—Preventative therapy with topiramate significantly reduced migraine frequency. Larger multicenter clinical studies may further delineate the role of topiramate in migraine prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1526-4610.2001.01190.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 196

Metadata

Authors
Storey, J. R., Calder, C. S., Hart, D. E., & Potter, D. L.
Venue
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Published
2001-12
Volume
41
Issue
10
Pages
968-975
ISSN
  • 0017-8748 (ISSN-L)
  • 1526-4610
OpenAlex
W2026080368
Cited by
196
References
0
FWCI
9.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study. https://app.cochat.ai/papers/10.1046/j.1526-4610.2001.01190.x
The paper
Storey, J. R., Calder, C. S., Hart, D. E., & Potter, D. L. (2001). Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1046/j.1526-4610.2001.01190.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.